IL212664A0 - Use of eef1a as biomarker and a method of screening metap2 inhibitors - Google Patents

Use of eef1a as biomarker and a method of screening metap2 inhibitors

Info

Publication number
IL212664A0
IL212664A0 IL212664A IL21266411A IL212664A0 IL 212664 A0 IL212664 A0 IL 212664A0 IL 212664 A IL212664 A IL 212664A IL 21266411 A IL21266411 A IL 21266411A IL 212664 A0 IL212664 A0 IL 212664A0
Authority
IL
Israel
Prior art keywords
eef1a
biomarker
screening
metap2 inhibitors
metap2
Prior art date
Application number
IL212664A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of IL212664A0 publication Critical patent/IL212664A0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL212664A 2008-11-06 2011-05-03 Use of eef1a as biomarker and a method of screening metap2 inhibitors IL212664A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08019432 2008-11-06
PCT/EP2009/007102 WO2010051882A1 (en) 2008-11-06 2009-10-05 Use of eef1a as biomarker and a method of screening metap2 inhibitors

Publications (1)

Publication Number Publication Date
IL212664A0 true IL212664A0 (en) 2011-07-31

Family

ID=41409225

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212664A IL212664A0 (en) 2008-11-06 2011-05-03 Use of eef1a as biomarker and a method of screening metap2 inhibitors

Country Status (8)

Country Link
US (1) US9151743B2 (enExample)
EP (1) EP2344665B1 (enExample)
JP (1) JP5347028B2 (enExample)
AU (1) AU2009313167C1 (enExample)
CA (1) CA2742737C (enExample)
ES (1) ES2402564T3 (enExample)
IL (1) IL212664A0 (enExample)
WO (1) WO2010051882A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
KR101712982B1 (ko) * 2015-07-31 2017-03-07 고려대학교 산학협력단 비알콜성지방간 조절인자 14-3-3 단백질
WO2018148638A1 (en) * 2017-02-10 2018-08-16 Zafgen, Inc. Pharmaceutical compositions of metap-2 inhibitors
CN108611352B (zh) * 2018-04-20 2020-08-07 华南农业大学 一种拟禾本科根结线虫翻译延长因子Mg-eEF1A及其防治植物病害的应用
CA3170118A1 (en) * 2020-02-06 2021-08-12 The Regents Of The University Of California Elongation factor 1-alpha inhibitors and uses thereof
CN116395718B (zh) * 2023-04-12 2024-12-17 中国科学院长春应用化学研究所 一种弱碱性钠盐纳米药物、其制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
EP1337854A2 (en) * 2000-11-14 2003-08-27 Novartis AG Method for screening anti-proliferative compounds and inhibiting tumor growth
US20020182701A1 (en) * 2001-08-30 2002-12-05 Saint Louis University Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
US20030232383A1 (en) 2001-11-02 2003-12-18 Sylvia Daunert Novel reagentless sensing system for measuring carbohydrates based on the galactose/glucose binding protein

Also Published As

Publication number Publication date
US20110275088A1 (en) 2011-11-10
EP2344665B1 (en) 2013-01-23
AU2009313167C1 (en) 2014-06-12
AU2009313167A1 (en) 2011-06-23
US9151743B2 (en) 2015-10-06
JP5347028B2 (ja) 2013-11-20
ES2402564T3 (es) 2013-05-06
CA2742737C (en) 2018-05-29
CA2742737A1 (en) 2010-05-14
JP2012507268A (ja) 2012-03-29
WO2010051882A1 (en) 2010-05-14
EP2344665A1 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
IL233095A0 (en) Biomarkers based on ratio and methods for their use
EP2255263A4 (en) REACHEMINER WITH TWO REFERENCE CLOCKS AND ITS ACTUATION METHOD
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
EP2358463A4 (en) INDIRECT AND DIRECT METHOD FOR THE SEQUESTRATION OF POLLUTANTS
PL2376507T3 (pl) Sposób otrzymywania hydroksymetylofosfonianów
IL212664A0 (en) Use of eef1a as biomarker and a method of screening metap2 inhibitors
GB0810990D0 (en) Device and method of making solid beads
ZA201107666B (en) Multi-ram drill rig and method of operation
GB0701599D0 (en) Method of detection
IL213064A0 (en) Method of determining a characteristic
ZA201105571B (en) Method of blasting
GB0817384D0 (en) Method of providing location data
ZA201107487B (en) Substituted 4-amino-5-benzoyl-2(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
GB0802009D0 (en) Biomarkers of aminopeptidase inhibition
PL2312271T3 (pl) Sposób określania wielkości dotyczących stanu morza
PL2411376T3 (pl) Inhibitory nf-kb
EP2431738A4 (en) SCREENING PROCESS FOR OSTEOPONTIN INHIBITOR AND INHIBITOR MANUFACTURED THEREWITH
GB0710636D0 (en) Method of indentifiying biomarkers
GB0813688D0 (en) Method of determination
GB0713774D0 (en) Method of determination
PL385436A1 (pl) Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny
GB0710768D0 (en) Method of identifying biomarkers
PL385483A1 (pl) Sposób wyznaczania właściwości dysypatywno-sprężystych materiałów
GB0809975D0 (en) A multi-optic rule and method of use
GB0613968D0 (en) Method of determination

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed